Literature DB >> 2987122

True versus immunoreactive angiotensin II in human plasma.

J Nussberger, D B Brunner, B Waeber, H R Brunner.   

Abstract

To measure specifically angiotensin-(1-8)octapeptide, peptides were extracted from 2 ml of plasma by reversible adsorption to bonded-phase silica. The angiotensin-(1-8)octapeptide was then isolated by isocratic reversed-phase high-performance liquid chromatography and quantified by radioimmunoassay. The extraction recovery of 125I-angiotensin II added to 2 ml of plasma was 99 +/- 2% (mean +/- SD). The overall recovery of 5, 10, and 20 fmol unlabeled angiotensin II added to 1 ml of plasma was 80 +/- 10%. The coefficient of variation for within-assay precision was 0.06 and for between-assay precision 0.13. The detection limit was 0.4 fmol/ml. Buffer and plasma blanks were below the detection limit. Normal subjects on a free diet in supine position averaged 4.2 +/- 1.7 fmol/ml angiotensin-(1-8)octapeptide. Furosemide (40 mg p.o.) and standing increased these values to 22 +/- 7.6 fmol/ml. In four volunteers, immunoreactive "angiotensin II" (more or less angiotensin-like material) was measured serially before and after converting-enzyme inhibition (Hoe 498) with conventional Dowex extraction. At peak inhibition, plasma immunoreactive "angiotensin II" levels decreased by only 44%. In contrast, angiotensin-(1-8)-octapeptide isolated by high-performance liquid chromatography completely disappeared. In hypertensive patients receiving long-term treatment with enalapril, plasma levels of angiotensin-(1-8)octapeptide fell from 2.7 +/- 0.9 to 0.9 +/- 0.3 fmol/ml (mean +/- SEM) 2 hours after the morning dose, whereas levels of immunoreactive "angiotensin II" were not significantly changed. We found that this sensitive method specifically measured angiotensin-(1-8)octapeptide and demonstrated that true angiotensin II virtually disappears during converting-enzyme inhibition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987122     DOI: 10.1161/01.hyp.7.3_pt_2.i1

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

1.  Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.

Authors:  Jaspal Patil; Alexander Schwab; Juerg Nussberger; Thomas Schaffner; Juan M Saavedra; Hans Imboden
Journal:  Regul Pept       Date:  2010-03-24

2.  Prenatal corticosterone exposure results in altered AT1/AT2, nephron deficit and hypertension in the rat offspring.

Authors:  Reetu R Singh; Luise A Cullen-McEwen; Michelle M Kett; Wee-Ming Boon; John Dowling; John F Bertram; Karen M Moritz
Journal:  J Physiol       Date:  2007-01-04       Impact factor: 5.182

3.  Influence of the renin-angiotensin system on sympathetic neurotransmission in canine skeletal muscle in vivo.

Authors:  J H Schwieler; T Kahan; J Nussberger; P Hjemdahl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

4.  Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.

Authors:  G Waeber; M Burnier; M Porchet; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?

Authors:  Mark C Chappell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

Review 6.  Renin inhibitors: cardiovascular drugs of the future?

Authors:  J M Wood; P Close
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

7.  Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry.

Authors:  Mark Lortie; Steven Bark; Roland Blantz; Vivian Hook
Journal:  Anal Biochem       Date:  2009-07-16       Impact factor: 3.365

8.  A neonate with idiopathic hyperaldosteronism.

Authors:  R H Veenhoven; J G Vande Walle; R A Donckerwolcke; J M Wit; A W Griffiven; F H Derkx; M A Schalekamp
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

9.  Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.

Authors:  M Neubeck; D Fliser; M Pritsch; K Weisser; M Fliser; J Nussberger; E Ritz; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 10.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.